BioDatomicsTM, a provider of bioinformatics analysis software and services that improve the productivity of genomic research, has received a grant from the National Institutes of Health (NIH) and a capital investment from the Maryland Department of Business and Economic Development (MDBED) Maryland Venture Fund (MVF) These strategic investments will allow the company to further expand the capabilities of its next generation sequencing (NGS) data analysis platform, BioDTTM.
NIH continues to support NGS projects that focus on addressing the Big Data challenges associated with genomic research and on democratizing access to advanced analysis platforms. With this NIH grant, ‘Building an open-source cloud-based computing platform to improve data access,’ BioDatomics will further expand its open-source toolset, bringing these additional capabilities to researchers and bioinformatics alike.
‘BioDatomics and the NIH share a common goal of accelerating genomic discoveries,’ said Alan Taffel, President of BioDatomics. ‘While NGS funding has traditionally focused on generating new data, there is now a clear need for NGS users to be able to glean insights from these data more quickly and intuitively. ”
In addition to the NIH grant, BioDatomics also received an investment from the MVF, which provides capital to innovative technology companies based in Maryland. Recognizing the avalanche of NGS data generated by academic and commercial research organizations and the need to analyze these data more efficiently, MVF took the opportunity to invest in a platform created specifically for this purpose.
‘BioDatomics operates at the intersection of two of Maryland’s fastest-growing sectors, biotechnology and big data. We are proud to make this investment in BioDatomics and look forward to their growth and success in Maryland,” said DBED Secretary Dominick Murray. ‘Supporting entrepreneurs and small businesses in high-tech, high-growth industries is crucial to the success of our economy and the state. Companies like BioDatomics are facilitating the development of state-of-the-art medicines, vaccines and technologies that keep us safer, healthier and better connected than ever before. ”
‘The investment from the Maryland Venture Fund serves as a validation of our approach and provides significant strategic value beyond financial commitment,’ Taffel said.
Although several companies have recently entered the NGS data analysis market, BioDatomics is the only company to develop an open-source solution built on the popular and powerful Hadoop® Big Data analysis engine that allows pipelines to run up to 100 times faster than traditional platforms. BioDT also improves productivity by integrating a number of popular genomic analysis tools into a single platform that provides drag-and-drop editing, real-time collaboration, visualized results, and intuitive table manipulation. The platform is available as a software license and will soon be released as a cloud-based service.
For more information, please stop at the BioDatomics booth during the Bio-IT World Conference & Expo taking place from April 29 to May 1 in Boston or visit Biodamics Com Biodamics Com